Domain Therapeutics S.A.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Domain Therapeutics S.A.
The French firm is going it alone for the first time with a planned Phase I trial for its lead EP4 receptor antagonist in cancer after years of sharing its technology and GCPR expertise with big pharma.
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Faust Pharmaceuticals
- Domain Therapeutics NA Inc.
- Kaldi Pharma
- Mavalon Therapeutics
- Neurofit SAS
- Prestwick Chemical SAS
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.